Datapoint: Roche to Acquire Good Therapeutics

Roche has entered a $250 million deal to acquire an immuno-oncology program from Good Therapeutics, a Seattle-based biotech. The deal is anticipated to close in the third quarter of 2022, and will give Roche full rights to Good’s PD1-regulated IL-2 receptor agonist program. “[The program] nicely complements our efforts on next-generation PD-1-targeted IL-2 therapeutics and our broader oncology strategy of providing cancer patients with innovative solutions and improving health outcomes,” James Sabry, Roche’s global head of pharma partnering, said in a news release. Roche’s existing PD-L1 therapy, Tecentriq, is a blockbuster, bringing in $3.63 billion in global sales as the French drugmaker’s no. 3 bestselling drug. Evaluate Pharma projects it will be Roche’s no. 2 bestseller by 2023, reaching $4.93 billion in global sales.

From Evaluate Pharma

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today